Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

AbbVie’s venetoclax set for early access in UK

Drug for CLL patients included in EAMS by MHRA

- PMLiVE

NICE backs Xalkori for lung cancer, but may cut two others from CDF

Preliminary verdict could lead to removal of Novartis' Afinitor and Janssen's Imbruvica from the Fund

Gilead Sciences

Gilead’s Truvada cleared for HIV prevention in EU

May help slow down recent uptick in new HIV diagnoses

AstraZeneca AZ

AZ-Lilly start second pivotal trial of fast-tracked Alzheimer’s drug

AMARANTH could be first treatment to target underlying mechanism

FDA approves Lilly-backed Bluetooth insulin device

Clears Companion Medical’s Bluetooth-enabled pen and smartphone app

Lilly promotes Joshua Smiley to new finance role

He will replace Thomas Grein, who is retiring in next month

- PMLiVE

AstraZeneca’s Alastair MacDonald joins ClinTec

Takes up role at the Scottish CRO as global head of clinical operations

- PMLiVE

Why your gran’s not too old to be a millennial

And what does age really have to do with being a millennial? 

- PMLiVE

Pfizer rides out Sanofi and confirms $14bn Medivation takeover

Success of cancer specialist’s drug Xtandi followed by work on other cancer drugs

Sanofi reception

Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

FDA verdict on Novo Nordisk’s rival combo Xultophy due next month 

Meet Anthill at conferences in London

October, the month of multichannel pharma marketing in London. Meet us at DigiPharm and Multichannel Excellence Summit

Anthill Agency

- PMLiVE

Portola rejection hands advantage to Boehringer’s Pradaxa

FDA’s ruling on reversal agent for NOACs unexpected

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links